Literature DB >> 8242797

Activation of the complement system by the capsule of Cryptococcus neoformans.

T R Kozel1.   

Abstract

In vitro studies indicate that encapsulated cryptococci are among the most powerful particulate activators of the complement system reported to date. The capsule itself is the site at which activation occurs. Activation occurs solely via the alternative complement pathway. Initiation occurs at apparently random focal sites in the capsule that expand through alternative pathway amplification to fill the capsule with C3 fragments. The C3 fragments are rapidly converted to iC3b, suggesting that phagocyte receptors for iC3b will be important in phagocytosis of the yeast. There is abundant evidence that a similar form of activation occurs in vivo during a cryptococcal infection. Cryptococcemia in humans and experimental animals is accompanied by a depletion of serum complement levels. Studies with complement deficient guinea pigs and mice indicate that the complement system plays an essential role in resistance to cryptococcosis. It is likely that the complement system contributes to host resistance by opsonization of the yeast to facilitate attachment and ingestion by phagocytic cells as well as by releasing chemotactic fragments of the complement cascade which contribute to the inflammatory response. The absence or unavailability of a functional complement system in the central nervous system may account in part for the predilection of the yeast for the brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242797

Source DB:  PubMed          Journal:  Curr Top Med Mycol        ISSN: 0177-4204


  8 in total

1.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 2.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

3.  Susceptibilities of Cryptococcus neoformans strains to platelet binding in vivo and to the fungicidal activity of thrombin-induced platelet microbicidal proteins in vitro.

Authors:  S Nail; R Robert; F Dromer; A Marot-Leblond; J M Senet
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Host defence to pulmonary mycosis.

Authors:  C H Mody; P W Warren
Journal:  Can J Infect Dis       Date:  1999-03

Review 5.  Role of microglia in fungal infections of the central nervous system.

Authors:  George W Koutsouras; Raddy L Ramos; Luis R Martinez
Journal:  Virulence       Date:  2016-11-18       Impact factor: 5.882

6.  Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi.

Authors:  Nadia R Cohen; Raju V V Tatituri; Amariliz Rivera; Gerald F M Watts; Edy Y Kim; Asako Chiba; Beth B Fuchs; Eleftherios Mylonakis; Gurdyal S Besra; Stuart M Levitz; Manfred Brigl; Michael B Brenner
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

7.  Laccase and melanization in clinically important Cryptococcus species other than Cryptococcus neoformans.

Authors:  Reiko Ikeda; Takashi Sugita; Eric S Jacobson; Takako Shinoda
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 8.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.